If you've been following the medical device (and/or pharmaceutical)
space for a while, you know that congestive heart failure is one of the
nastiest, hardest to treat, chronic conditions out there. There's really
no way to reverse the disease short of a heart transplant, and the
drugs and device therapies available sort themselves out between
"largely ineffective" and "effective, but with serious issues".
That's terrible news for those patients who have congestive heart failure, but it leaves a tremendous opportunity for Sunshine Heart (NSDQ:SSH).
This small-cap med-tech from Minnesota appears to have an ingenious
solution to the problem, one that is based around well-understood
principles and relatively simple technology. Although it will be at
least four to five years before commercialization in the U.S., and
that's only if the pivotal study shows adequate efficacy and an
acceptable risk/benefit profile, this is definitely a name to watch in
the med-tech space as the company looks to bring a new option to the
table for seriously ill CHF patients.
Read the full article here:
http://www.massdevice.com/blogs/massdevice/despite-long-road-ahead-sunshine-heart-worth-serious-look
No comments:
Post a Comment